Canute Scott A
SEC-identified person · CIK 1303416 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Oncorus, Inc. ONCR | Director | filed 2020–2022 |
| Flexion Therapeutics Inc FLXN | Director | filed 2015–2021 |
| Immunomedics INC IMMU | Director | filed 2017–2020 |
| Akebia Therapeutics, Inc. AKBA | Director | filed 2016–2019 |
| Protara Therapeutics, Inc. TARA | Director | filed 2015–2018 |
| Outlook Therapeutics, Inc. OTLK | Director | filed 2016–2017 |
| Genzyme Corp u4yfvwk$ | Executive VP | filed 2010–2011 |
| Lilly ELI & CO LLY | President, Mfg. Operations | filed 2006–2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.